In the first half of FY2026, as global demand continued to recover, the initiatives we have pursued—strengthening our product lineup, branding through collaboration with KOLs, and reinforcing our global sales structure covering more than 140 countries—proved effective, and the Dental, Surgical, Industrial, and DCI businesses each achieved double-digit sales growth. As a result, consolidated net sales were JPY 47.2 billion, EBITDA was JPY 12.7 billion, and operating profit was JPY 10.0 billion. In addition, due to foreign exchange gains resulting from yen depreciation, ordinary profit was JPY 11.5 billion and profit attributable to owners of parents amounted to JPY 8.1 billion.

In the Mid Term Management Plan “NV2030” announced last August, we identified the Dental business in North America and the Surgical business as growth drivers. Both businesses grew steadily and played a leading role in our overall business growth during the period. Although the North American market as a whole remained flat, the NSK brand continued to expand its market share. This, combined with progress in bundled sales of NSK and DCI products, steadily enhanced the NAKANISHI Group’s market presence in North America. In the Surgical business, we also completed an M&A transaction, bringing U.S. medical device manufacturer Acra Cut into the NAKANISHI Group. With Acra Cut and its exceptionally strong brand now part of the Group, we expect the Surgical business to achieve further growth.

Leveraging the “grinding technology” we have honed since our founding, we will create “brilliant progress” in this world. To realize our mission, all employees of the NAKANISHI Group around the world will move forward as ONE TEAM.